Please use this identifier to cite or link to this item: http://hdl.handle.net/11455/66659
標題: Expression and Immunological Studies of Classical Swine Fever Virus Glycoprotein E2 in the Bi-Cistronic Baculovirus/Larvae Expression System
作者: Wu, C.M.
宣詩玲
Hsuan, S.L.
Chen, Z.W.
Jinn, T.R.
Huang, C.J.
Liao, J.W.
Chen, T.H.
Liao, C.M.
Lee, W.C.
Wu, T.Y.
Chien, M.S.
廖俊旺
黃千衿
關鍵字: baculovirus;bi-cistronic;classical swine fever virus (CSFV) E2;glycoprotein;green fluorescent protein (GFP);Trichoplusia ni larvae;insect larvae;protein-production;subunit vaccine;marker vaccine;pigs;purification;protection;antibodies;efficacy;disease
Project: Bioscience Biotechnology and Biochemistry
期刊/報告no:: Bioscience Biotechnology and Biochemistry, Volume 74, Issue 7, Page(s) 1343-1349.
摘要: 
To develop an economical, easy technique for producing recombinant E2 glycoprotein (rE2) of classical swine fever virus (CSFV) as a candidate immunogen, a bi-cistronic baculovirus/larvae expression vector was constructed using p10 promoter, an internal ribosome entry site, and the gfp gene. Trichoplusia ni larvae were successfully infected with the occluded recombinant baculovirus via feed, and the characteristics of rE2 were confirmed by immunoblot and glycosylation stain. rE2 at a concentration of 0.6-0.8 mg/ml without degradation was obtained from hemolymphs of infected larvae that emitted high levels of green fluorescence. Immunization assays indicated that mice and piglets immunized with rE2-containing hemolymph elicited high titers of anti-CSFV E2 antibodies with virus-neutralizing activity. This is the first study to indicate that baculovirus/T. ni larvae-expressed rE2 can be served as a vaccine candidate. This system provides an economical alternative for the production of vaccine components in the veterinary industry.
URI: http://hdl.handle.net/11455/66659
ISSN: 0916-8451
DOI: 10.1271/bbb.90894
Appears in Collections:微生物暨公共衛生學研究所

Show full item record
 

Google ScholarTM

Check

Altmetric

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.